Cromolyn
As of the edition of 20 October 2026, Cromolyn is a small molecule: marketed, first approved in 1981 (CA).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1988
- Kind
- Small molecule
- Brand name
- Intal
- First approved
- 31 December 1981 (CA)
- Approvals on record
- 10 in 4 regions
- Holder of the most recent approval
- Blacksmith Brands; 9 holders in all
- Registered trials
- 18, 5 stopped early
- Disease areas
- Nervous system; Skin and connective tissue; Cancer; Lungs and airways; Digestive system; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 4 | 2 | 1 |
| Phase 2 | 8 | 3 | 3 | 2 |
| Phase 3 | 2 | 0 | 0 | 2 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 18 |